Pharmaceutical News

RSS

Combination therapy improves outcomes for liver cancer patients: Study

A combination of an oral drug, called sorafenib, and a method for injecting microbeads of chemotherapy directly into tumors has been proven safe for liver cancer patients and may improve outcomes for those who have these fast-growing, deadly tumors whose numbers are on the rise in the U.S.

1 Oct 2011

Public health officials should determine community storage of anthrax-preventing antibiotics

As part of preparations for a possible large-scale anthrax attack, public health officials on the state and local levels should determine where and how anthrax-preventing antibiotics should be stored in their communities, says a new report from the Institute of Medicine.

1 Oct 2011

Tips for seniors to avoid serious complications from prescription meds

For seniors, October is a month in which medications - particularly prescription meds - will likely be on their minds. Not only is October national "Talk About Prescriptions Month," but Oct. 15 marks the start of Medicare's Annual Election Period during which beneficiaries can disenroll from, switch or enroll into a Medicare Advantage or Part D plan.

1 Oct 2011

Walgreens, Walmart partner with Coventry to offer First Health Value Plus in the U.S.

Coventry Health Care, Inc. announced today that it has joined in partnership for 2012 with the nation's largest and best known names in retail and pharmacy—Walgreens, Walmart, and Target—to offer a novel Medicare prescription drug plan known as First Health Value Plus.

1 Oct 2011

CorMedix to primarily focus on commercialization of Neutrolin in Europe

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced it has decided based upon recent developments to primarily focus on the commercialization of Neutrolin in Europe.

1 Oct 2011

ViroPharma licenses worldwide rights from Intellect Neurosciences to OX1 for treatment of FA

ViroPharma Incorporated today announced the license of worldwide rights from Intellect Neurosciences, Inc. to its clinical stage drug candidate, OX1, being developed for the treatment of Friedreich's Ataxia (FA), a rare, hereditary, progressive neurodegenerative disease.

1 Oct 2011

Blueberry powder may control triple negative breast cancer

In several studies recently conducted at the Beckman Research Institute at the City of Hope, Duarte, CA researchers found that feeding blueberry powder to mice significantly reduced the growth and spread of triple negative breast cancer cells, a very aggressive form of cancer.

1 Oct 2011

Express Scripts launches suite of services through HealthBridge Pharma & Biotech

Express Scripts has launched a suite of services for pharmaceutical and biotech companies through HealthBridge Pharma & Biotech, providing a single-solution approach to patient care.

1 Oct 2011

CMA welcomes Supreme Court ruling on Vancouver's supervised injection facility

The Canadian Medical Association (CMA) welcomed today the unanimous ruling by the Supreme Court of Canada allowing Vancouver's supervised drug injection facility, Insite, to continue to operate.

1 Oct 2011

Poll: 21.4% of Americans believe vaccines can cause autism

More than one-quarter of Americans are concerned about the value and safety of vaccines and 21.4 percent believe vaccines can cause autism, according to the Thomson Reuters-NPR Health Poll.

1 Oct 2011

UCI study shows promise of metabolic therapy for autoimmune diseases

A glucosamine-like dietary supplement suppresses the damaging autoimmune response seen in multiple sclerosis, according to a UC Irvine study.

1 Oct 2011

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian Technologies Limited is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate clinical studies of VGX-100.

1 Oct 2011

ADVENTRX holds Type A meeting with FDA to discuss Exelbine NDA

ADVENTRX Pharmaceuticals, Inc. announced today that it held a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) it received in August from the FDA regarding the Company's New Drug Application (NDA) for Exelbine (vinorelbine injectable emulsion) for the treatment of non-small cell lung cancer.

1 Oct 2011

Galectin posts new corporate video on galectin-inhibiting therapeutics to treat fibrosis and cancer

Galectin Therapeutics Inc. today announced that it posted a new corporate presentation video to its website, www.galectintherapeutics.com, that highlights the Company's leadership position in developing galectin-inhibiting therapeutics to treat fibrosis and cancer.

30 Sep 2011

FDA, other regulatory and international partners complete International Internet Week of Action

The U.S. Food and Drug Administration and other regulatory and international partners have completed the International Internet Week of Action (IIWA), a cooperative effort to curb online sales and distribution of counterfeit and illegal medical products.

30 Sep 2011

MU researchers examine use of propranolol to improve primary traits linked with autism

Most drug therapy interventions for people with autism have targeted psychiatric problems, including aggression, anxiety and obsessive behavior. Now, University of Missouri researchers are examining the use of propranolol to improve the primary traits associated with autism - difficulty with normal social skills, language and repetitive behaviors.

30 Sep 2011

Study highlights importance of prior planning before introduction of new vaccines

Proper planning before the introduction of new vaccines into a developing country's active immunization program could prevent storage problems and transportation bottlenecks that decrease the availability of existing vaccines by as much as two-thirds, according to a University of Pittsburgh study.

30 Sep 2011

Patients with chronic hepatitis C less likely to take medications over time

Patients being treated for chronic hepatitis C become less likely to take their medications over time, according to a new study from the Perelman School of Medicine at the University of Pennsylvania.

30 Sep 2011

APhA encourages patients to discuss with pharmacist about pain and medications

In honor of Pain Awareness Month, the American Pharmacists Association (APhA) encourages patients to have an open discussion with their pharmacist about their pain and the medications they take for pain.

30 Sep 2011

Survey: 25% of employers have little or no understanding of specialty pharmacy, costs

Twenty-five percent of employers have little or no understanding of specialty pharmacy and 53 percent have only a moderate understanding of this challenging benefit according to a new survey released by the non-profit Midwest Business Group on Health (MBGH), one of the nation's leading business groups of private and public employers.

30 Sep 2011

Pharmaceutical News

Combination therapy improves outcomes for liver cancer patients: Study

Public health officials should determine community storage of anthrax-preventing antibiotics

Tips for seniors to avoid serious complications from prescription meds

Walgreens, Walmart partner with Coventry to offer First Health Value Plus in the U.S.

CorMedix to primarily focus on commercialization of Neutrolin in Europe

ViroPharma licenses worldwide rights from Intellect Neurosciences to OX1 for treatment of FA

Blueberry powder may control triple negative breast cancer

Express Scripts launches suite of services through HealthBridge Pharma & Biotech

CMA welcomes Supreme Court ruling on Vancouver's supervised injection facility

Poll: 21.4% of Americans believe vaccines can cause autism

UCI study shows promise of metabolic therapy for autoimmune diseases

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

ADVENTRX holds Type A meeting with FDA to discuss Exelbine NDA

Galectin posts new corporate video on galectin-inhibiting therapeutics to treat fibrosis and cancer

FDA, other regulatory and international partners complete International Internet Week of Action

MU researchers examine use of propranolol to improve primary traits linked with autism

Study highlights importance of prior planning before introduction of new vaccines

Patients with chronic hepatitis C less likely to take medications over time

APhA encourages patients to discuss with pharmacist about pain and medications

Survey: 25% of employers have little or no understanding of specialty pharmacy, costs

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News